To ensure scientific breakthroughs for HIV/AIDS are continued to be pursued, President Barack Obama on 2 December pledged $5bn to the Global Fund to Fight AIDS, Tuberculosis and Malaria and said his administration was redirecting $100m to the National Institutes of Health (NIH) toward finding a cure for HIV.
Obama pledges $5bn to AIDS fund, directs $100m to NIH for cure
To ensure scientific breakthroughs for HIV/AIDS are continued to be pursued, President Barack Obama on 2 December pledged $5bn to the Global Fund to Fight AIDS, Tuberculosis and Malaria and said his administration was redirecting $100m to the National Institutes of Health (NIH) toward finding a cure for HIV.
More from Immunological
• By
Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.
• By
J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.